Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the evolving treatment landscape of polycythemia vera (PV), focusing on the role of the newly approved hepcidin mimetic rusfertide. Dr Pemmaraju highlights findings from the Phase II REVIVE (NCT04057040) and Phase III VERIFY (NCT05210790) trials, exploring improvements in hematocrit control, phlebotomy requirements, and symptom burden, alongside the potential integration of rusfertide into existing treatment strategies. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.